CO4990962A1 - Compuestos 4-(2-ceto-1-benzilimida-zolinil) piperidina como antagonistas del receptor orl1 - Google Patents
Compuestos 4-(2-ceto-1-benzilimida-zolinil) piperidina como antagonistas del receptor orl1Info
- Publication number
- CO4990962A1 CO4990962A1 CO99002592A CO99002592A CO4990962A1 CO 4990962 A1 CO4990962 A1 CO 4990962A1 CO 99002592 A CO99002592 A CO 99002592A CO 99002592 A CO99002592 A CO 99002592A CO 4990962 A1 CO4990962 A1 CO 4990962A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- independently selected
- alkynyl
- alkenyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un compuesto con la siguiente fórmula I:o las sales farmacéuticamente aceptables del mismo, en la que R1 y R2 son independientemente alquilo C1 -C4 ; R1 y R2 , junto con el átomo de carbono al que están unidos forman un grupo mono-, bi-, tri- oespirocíclico que tiene entre 6 y 13 átomos de carbono, en el que el grupo cíclico está opcionalmente sustituido con uno a cinco sustituyentes independientemente seleccionados entre alquilo C1 -C4 , alquileno C2 -C4 , alcoxi C1 -C4 , hidroxi, oxo, =CH2 y =CH-alquilo C1 -C4 ;R3 es alquilo C1 -C7 , alquenilo C2 -C5 , alquinilo C2 -C5 , fenil-alquilo-C1 -C5 , fenilo opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados entre flúor, alquilo C1 -C3 y alcoxi C1 -C3 , o un grupo heteroarilo seleccionado entre furilo, tienilo, pirrolilo y piridilo, en el que dicho grupo heteroarilo está opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados entre halógeno, alquilo C1 -C3 y alcoxi C1 -C3 , con la condición de que cuando ambos R1 y R2 son alquilo C1 -C4 , entonces R3 es distinto a alquilo C1 -C7 , alquenilo C2 -C5 y alquinilo C2 -C5 ; R4 se selecciona entre:1) hidrógeno, 2) alquilo (C1 -C8 ), cicloalquilo (C3 -C7 ), alquenilo (C2 -C8 ), alquinilo (C2 -C8 ), alquilo (C1 -C6 )-Z-, alquilo (C1 -C6 )-Z-alquilo (C1 -C6 ), cicloalquilo (C3 -C7 )-Z-alquilo (C1 -C6 ), alquenilo (C2 -C6 )-Z-alquilo (C1 -C6 ) o alquinilo (C2 -C6 )- Z-alquilo (C1 -C6 ), opcionalmente mono o disustituido donde Z se selecciona entre O, S, SO, SO2 , CO, CO2 , OCO, NR, CONR y NRCO, donde R es hidrógeno o alquilo (C1 -C6 ) y los sustituyentes a unirse al radical alquilo, alquenilo, alquinilo o cicloalquilo se seleccionan independientemente entre halógeno, - 2 -hidroxi, carboxi, amino, monoAND#8209; o diAND#8209;(alquil C1 AND#8209;C4 ) amino, hidrazino, azido, ureido, amidino y guanidino; o 3) arilo, heterocíclico, arilalquilo (C1 AND#8209;C5 ), heterocíclico alquilo (C1 AND#8209;C5 ), heterocíclicoAND#8209;heterocíclico alquilo (C1 AND#8209;C5 ); arilheterocíclico alquilo (C1 AND#8209;C5 ); heterocíclicoAND#8209;ZAND#8209;alquilo (C1 AND#8209;C5 ), arilAND#8209;ZAND#8209;alquilo (C1 AND#8209;C5 ), arilalquilo (C1 AND#8209;C5 )AND#8209;ZAND#8209;alquilo (C1 AND#8209;C5 ) o heterocíclico alquilo (C1 AND#8209;C5 )AND#8209;ZAND#8209;alquilo (C1 AND#8209;C5 ), opcionalmente mono o disustituido, en el que Z se selecciona entre O, S, SO, SO2 , CO, CO2 , OCO, NR, CONR y NRCO, en el que R es hidrógeno o alquilo (C1 AND#8209;C6 ) y los sustituyentes a los que se une el radical arilo o heterocíclico se seleccionan independientemente entre halógeno, hidroxi, carboxi, alquilo (C1 AND#8209;C4 ), halo alquilo (C1 -C4 ), alcoxi (C1 AND#8209;C4 ), alquilo (C1 AND#8209;C4 )AND#8209;COAND#8209;, alquil (C1 AND#8209;C4 ) aminoAND#8209;COAND#8209;, fenilo, bencilo, amino, monoAND#8209; o di(alquil C1 AND#8209;C4 )amino, hidrazino, azido, ureido, amidino y guanidino; R5 se selecciona independientemente entre halógeno, alquilo C1 AND#8209;C3 , alcoxi C1 AND#8209;C3 , alquil (C1 AND#8209;C3 ) sulfonilo, CF3 , carboxi, hidroxi, amino, alquilamino, acilamino, arilcarbonilo, alquilcarbonilo e hidroxialquilo y n es 0, 1, 2, 3 ó 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB9800069 | 1998-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4990962A1 true CO4990962A1 (es) | 2000-12-26 |
Family
ID=11004651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99002592A CO4990962A1 (es) | 1998-01-19 | 1999-01-19 | Compuestos 4-(2-ceto-1-benzilimida-zolinil) piperidina como antagonistas del receptor orl1 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6423725B1 (es) |
| EP (1) | EP1049689B1 (es) |
| JP (1) | JP3342478B2 (es) |
| CN (1) | CN1288464A (es) |
| AP (1) | AP9901442A0 (es) |
| AR (1) | AR014421A1 (es) |
| AT (1) | ATE219772T1 (es) |
| AU (1) | AU1679099A (es) |
| BG (1) | BG104670A (es) |
| BR (1) | BR9907104A (es) |
| CA (1) | CA2317462C (es) |
| CO (1) | CO4990962A1 (es) |
| DE (1) | DE69901934T2 (es) |
| DK (1) | DK1049689T3 (es) |
| EA (1) | EA200000683A1 (es) |
| ES (1) | ES2175925T3 (es) |
| GT (1) | GT199900008A (es) |
| IL (1) | IL137149A0 (es) |
| IS (1) | IS5539A (es) |
| MA (1) | MA26598A1 (es) |
| NO (1) | NO20003671L (es) |
| OA (1) | OA11445A (es) |
| PA (1) | PA8467101A1 (es) |
| PE (1) | PE20000166A1 (es) |
| PL (1) | PL342046A1 (es) |
| PT (1) | PT1049689E (es) |
| TN (1) | TNSN99006A1 (es) |
| TR (1) | TR200002090T2 (es) |
| WO (1) | WO1999036421A1 (es) |
| ZA (1) | ZA99314B (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| ES2237047T3 (es) * | 1998-10-23 | 2005-07-16 | Pfizer Inc. | Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1. |
| WO2000031061A1 (fr) * | 1998-11-20 | 2000-06-02 | Banyu Pharmaceutical Co., Ltd. | Derives de 2-oxo-imidazole |
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| ES2223588T3 (es) * | 1999-10-13 | 2005-03-01 | Banyu Pharmaceutical Co., Ltd. | Derivados de imidazolidinona sustituidos. |
| WO2001039723A2 (en) | 1999-12-06 | 2001-06-07 | Euro-Celtique, S.A. | Triazospiro compounds having nociceptin receptor affinity |
| JP4028730B2 (ja) | 1999-12-06 | 2007-12-26 | ユーロ−セルティーク エス．エイ． | オピオイド受容体に対する親和性を有する３級アミノ化合物 |
| EP1242085B1 (en) * | 1999-12-06 | 2005-08-24 | Euro-Celtique, S.A. | Benzimidazole compounds having nociceptin receptor affinity |
| GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| JP4155029B2 (ja) | 2000-11-15 | 2008-09-24 | 萬有製薬株式会社 | ベンズイミダゾール誘導体 |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| KR100855204B1 (ko) | 2001-04-18 | 2008-09-01 | 유로-셀티크 소시에떼 아노뉨 | 노시셉틴 유사체 |
| CN1516584A (zh) | 2001-04-18 | 2004-07-28 | ŷ�����ǹɷ�����˾ | 螺吡唑化合物 |
| CA2443938C (en) | 2001-04-18 | 2010-06-22 | R. Richard Goehring | Spiroindene and spiroindane compounds as opioid ligands useful for treating pain |
| CA2444489C (en) * | 2001-04-18 | 2010-06-22 | Euro-Celtique, S.A. | Benzimidazolone compounds |
| SI1598339T1 (sl) * | 2001-04-18 | 2009-12-31 | Euro Celtique Sa | Derivati 1-(4-amino.cikloheksil)-1,3-dihidro-2h-benzimidazol-2-ona in sorodne spojine kot nociceptinski analogi in ORL1 ligandi za zdravljenje bolečine |
| DE10123163A1 (de) * | 2001-05-09 | 2003-01-16 | Gruenenthal Gmbh | Substituierte Cyclohexan-1,4-diaminderivate |
| JP3896309B2 (ja) | 2001-07-09 | 2007-03-22 | ファイザー株式会社 | プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体 |
| DK1491212T3 (da) * | 2002-03-29 | 2012-10-29 | Mitsubishi Tanabe Pharma Corp | Middel til behandling af søvnforstyrrelser |
| JP2005289816A (ja) * | 2002-05-14 | 2005-10-20 | Banyu Pharmaceut Co Ltd | ベンズイミダゾール誘導体 |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| AU2003296564A1 (en) * | 2002-11-12 | 2004-06-03 | Grunenthal Gmbh | 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives |
| AR045939A1 (es) | 2003-09-25 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos |
| AR045843A1 (es) | 2003-10-03 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| AR054816A1 (es) * | 2005-07-13 | 2007-07-18 | Banyu Pharma Co Ltd | Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos |
| US7300947B2 (en) * | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| WO2007061862A2 (en) * | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
| JP2009525269A (ja) | 2006-01-30 | 2009-07-09 | ユーロ−セルティーク エス．エイ． | カルシウムチャネルブロッカーとしての環状尿素化合物 |
| GB0605784D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| GB0605786D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| AU2007310209B2 (en) | 2006-10-16 | 2011-11-17 | Mitsubishi Tanabe Pharma Corporation | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
| SI2076506T1 (sl) * | 2007-01-16 | 2011-01-31 | Purdue Pharma Lp | Heterociklično substituirani piperidini kot ORL-1 ligandi |
| EP2128154B1 (en) * | 2007-03-01 | 2015-04-08 | Mitsubishi Tanabe Pharma Corporation | Benzimidazole compound and pharmaceutical use thereof |
| EP3101018B1 (en) | 2007-08-31 | 2019-03-06 | Purdue Pharma L.P. | Substituted-quinoxaline-type-piperidine compounds and the uses thereof |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| TW201016675A (en) * | 2008-09-16 | 2010-05-01 | Mitsubishi Tanabe Pharma Corp | Crystalline benzoimidazole compound and salt thereof |
| JP2013532149A (ja) * | 2010-06-17 | 2013-08-15 | ノバルティス アーゲー | ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体 |
| WO2014153529A1 (en) | 2013-03-22 | 2014-09-25 | The Scripps Research Institute | Substituted benzimidazoles as nociceptin receptor modulators |
| RU2019120099A (ru) * | 2016-11-28 | 2020-12-30 | Мицубиси Танабе Фарма Корпорейшн | Лекарственное средство для лечения кокаиновой наркозависимости или предотвращения ее рецидива |
| WO2019141803A1 (en) * | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
| CN116496270B (zh) * | 2022-01-27 | 2024-09-24 | 四川大学华西医院 | 一类4-氨基哌啶衍生物及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3161645A (en) | 1962-12-18 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds |
| US3318900A (en) | 1964-05-06 | 1967-05-09 | Janssen Pharmaceutica Nv | Derivatives of benzimidazolinyl piperidine |
| JPS58180481A (ja) | 1982-04-15 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
| AT388731B (de) | 1987-12-15 | 1989-08-25 | Gerot Pharmazeutika | Neue derivate von benzimidazol, ihre herstellung und verwendung |
| WO1997016186A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine agonists |
| ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| WO1997040035A1 (en) | 1996-04-19 | 1997-10-30 | Neurosearch A/S | 1-(4-piperidyl)-benzimidazoles having neurotrophic activity |
| WO1998054168A1 (fr) | 1997-05-30 | 1998-12-03 | Banyu Pharmaceutical Co., Ltd. | Derives de 2-0xoimidazole |
-
1999
- 1999-01-08 PT PT99900012T patent/PT1049689E/pt unknown
- 1999-01-08 JP JP2000540137A patent/JP3342478B2/ja not_active Expired - Fee Related
- 1999-01-08 CN CN99802227A patent/CN1288464A/zh active Pending
- 1999-01-08 TR TR2000/02090T patent/TR200002090T2/xx unknown
- 1999-01-08 BR BR9907104-5A patent/BR9907104A/pt not_active Application Discontinuation
- 1999-01-08 DK DK99900012T patent/DK1049689T3/da active
- 1999-01-08 PL PL99342046A patent/PL342046A1/xx not_active Application Discontinuation
- 1999-01-08 EP EP99900012A patent/EP1049689B1/en not_active Expired - Lifetime
- 1999-01-08 AT AT99900012T patent/ATE219772T1/de not_active IP Right Cessation
- 1999-01-08 DE DE69901934T patent/DE69901934T2/de not_active Expired - Fee Related
- 1999-01-08 IL IL13714999A patent/IL137149A0/xx unknown
- 1999-01-08 EA EA200000683A patent/EA200000683A1/ru unknown
- 1999-01-08 ES ES99900012T patent/ES2175925T3/es not_active Expired - Lifetime
- 1999-01-08 US US09/403,408 patent/US6423725B1/en not_active Expired - Fee Related
- 1999-01-08 CA CA002317462A patent/CA2317462C/en not_active Expired - Fee Related
- 1999-01-08 AU AU16790/99A patent/AU1679099A/en not_active Abandoned
- 1999-01-08 WO PCT/IB1999/000012 patent/WO1999036421A1/en not_active Application Discontinuation
- 1999-01-14 AP APAP/P/1999/001442A patent/AP9901442A0/en unknown
- 1999-01-15 MA MA25432A patent/MA26598A1/fr unknown
- 1999-01-15 PA PA19998467101A patent/PA8467101A1/es unknown
- 1999-01-15 TN TNTNSN99006A patent/TNSN99006A1/fr unknown
- 1999-01-18 AR ARP990100184A patent/AR014421A1/es unknown
- 1999-01-18 PE PE1999000041A patent/PE20000166A1/es not_active Application Discontinuation
- 1999-01-18 ZA ZA9900314A patent/ZA99314B/xx unknown
- 1999-01-19 GT GT199900008A patent/GT199900008A/es unknown
- 1999-01-19 CO CO99002592A patent/CO4990962A1/es unknown
-
2000
- 2000-06-16 IS IS5539A patent/IS5539A/is unknown
- 2000-07-07 OA OA1200000203A patent/OA11445A/en unknown
- 2000-07-18 NO NO20003671A patent/NO20003671L/no not_active Application Discontinuation
- 2000-08-07 BG BG104670A patent/BG104670A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1049689T3 (da) | 2002-07-22 |
| AP9901442A0 (en) | 1999-03-31 |
| DE69901934T2 (de) | 2002-11-07 |
| JP3342478B2 (ja) | 2002-11-11 |
| PA8467101A1 (es) | 2000-09-29 |
| AR014421A1 (es) | 2001-02-28 |
| MA26598A1 (fr) | 2004-12-20 |
| CN1288464A (zh) | 2001-03-21 |
| ZA99314B (en) | 2000-07-18 |
| NO20003671D0 (no) | 2000-07-18 |
| IL137149A0 (en) | 2001-07-24 |
| US6423725B1 (en) | 2002-07-23 |
| EA200000683A1 (ru) | 2000-12-25 |
| DE69901934D1 (de) | 2002-08-01 |
| OA11445A (en) | 2004-04-30 |
| ATE219772T1 (de) | 2002-07-15 |
| CA2317462C (en) | 2005-09-13 |
| TNSN99006A1 (fr) | 2005-11-10 |
| NO20003671L (no) | 2000-09-18 |
| PT1049689E (pt) | 2002-09-30 |
| PE20000166A1 (es) | 2000-03-07 |
| ES2175925T3 (es) | 2002-11-16 |
| CA2317462A1 (en) | 1999-07-22 |
| BG104670A (en) | 2001-05-31 |
| PL342046A1 (en) | 2001-05-21 |
| BR9907104A (pt) | 2000-10-24 |
| JP2002509148A (ja) | 2002-03-26 |
| EP1049689B1 (en) | 2002-06-26 |
| TR200002090T2 (tr) | 2000-11-21 |
| GT199900008A (es) | 2000-07-12 |
| EP1049689A1 (en) | 2000-11-08 |
| IS5539A (is) | 2000-06-16 |
| AU1679099A (en) | 1999-08-02 |
| WO1999036421A1 (en) | 1999-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4990962A1 (es) | Compuestos 4-(2-ceto-1-benzilimida-zolinil) piperidina como antagonistas del receptor orl1 | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| CR8468A (es) | Derivado de n-(1,5-difenil-1h-pirazol-3-il)metil)sulfonamida con afinidad por los receptores cb1 | |
| CO5611152A2 (es) | Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen | |
| AR053149A1 (es) | Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| AR055051A1 (es) | Compuestos de tiazol y oxazol y composiciones farmaceuticas que los contienen. | |
| AR049784A1 (es) | Derivados sustituidos de morfolina y tiomorfolina | |
| CO6321170A2 (es) | Heterociclos fusionados de ciclobutoxi amino y usos terapeuticos de los mismos | |
| MX2007003433A (es) | Sintesis de n-fluorobencil) -n- (1-metilpiperidin-4-il) -n'- (4- (2-metilpropiloxi) fenilmetil) carbamida y su sal de tartrato y formas cristalinas. | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| AR071617A1 (es) | Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. | |
| MX2009012885A (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco | |
| PE20120229A1 (es) | Compuestos heterociclicos como inhibidores de proteasa aspartica | |
| PE20001303A1 (es) | Derivados de la 4-aroilpiperidina como antagonistas del receptor ccr-3 | |
| ES2258642T3 (es) | Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina. | |
| CO6150147A2 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| AR047606A1 (es) | 4-oxobenzonitrilos como moduladores de receptores de androgenos,composiciones farmaceuticas que los contienen y usos | |
| EA199901102A1 (ru) | Производные азетидинилпропилпиперидина, промежуточные соединения и применение в качестве антагонистов тахикинина | |
| CO5631442A2 (es) | Nuevos derivados de indolizina 1,2,3 sustituida, inhibidores de los fgfs, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CO6160324A2 (es) | Heterociclos sustituidos que contienen nitrogeno como inhibidores del receptor adp plaquetario | |
| AR054072A1 (es) | 3-amino arilpropil indoles como inhibidores de reabsorcion de monoaminas. procesos de obtencion y composiciones farmaceuticas | |
| AR054414A1 (es) | Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas. |